Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2022 | eRAPID improves patient self-management of cancer treatment side-effects

Galina Velikova, MD, PhD, St. James’s University Hospital Leeds, Leeds, UK, provides an overview of eRAPID, the electronic self-reporting of adverse events for patients during and after cancer treatment. A randomized clinical trial involving eRAPID demonstrated a benefit to patients in managing their symptoms without increasing hospital workload. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.